RESEARCH ARTICLE

Predictors of Severe Sepsis among Patients Hospitalized for Community-Acquired Pneumonia

Beatriz Montull1**, Rosario Menéndez1**, Antoni Torres2, Soledad Reyes1, Raúl Méndez1, Rafael Zalacain3, Alberto Capelastegui4, Olga Rajas6, Luis Borderías6, Juan Martin-Villasclaras5, Salvador Bello6, Inmaculada Alfageme9, Felipe Rodríguez de Castro10, Jordi Rello11, Luis Molinos12, Juan Ruiz-Manzano13, NAC Calidad Group

1 Pneumology Department, ISS/Hospital Universitario y Politècnico La Fe, CIBER Enfermedades Respiratorias (CIBERES), Valencia, Spain, 2 Pneumology Department, Hospital Clínico y Provincial, IDIBAPS, CIBER Enfermedades Respiratorias (CIBERES), Barcelona, Spain, 3 Pneumology Department, Hospital Cruces, Vizcaya, Spain, 4 Pneumology Department, Hospital Galdakao, Vizcaya, Spain, 5 Pneumology Department, Hospital La Princesa, Madrid, Spain, 6 Pneumology Department, Hospital San Jorge, Huesca, Spain, 7 Pneumology Department, Hospital Carlos Haya, Málaga, Spain, 8 Pneumology Department, Hospital Miguel Servet, Zaragoza, Spain, 9 Pneumology Department, Hospital Valme, Sevilla, Spain, 10 Pneumology Department, Hospital Doctor Negrín Las Palmas, Gran Canaria, Spain, 11 Critical Care Department, Hospital Joan XXII de Tarragona and Hospital Vall Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, 12 Pneumology Department, Hospital Central Asturias, Oviedo, Asturias, Spain, 13 Pneumology Department, Hospital Germans Trias i Pujol Badalona, Barcelona, Spain

These authors contributed equally to this work.

☯ Current address: Dept. of Medicine-Doctoral Program, Barcelona Autonomous University, Barcelona, Spain

* rosmenend@gmail.com

Abstract

Background

Severe sepsis, may be present on hospital arrival in approximately one-third of patients with community-acquired pneumonia (CAP).

Objective

To determine the host characteristics and micro-organisms associated with severe sepsis in patients hospitalized with CAP.

Results

We performed a prospective multicenter cohort study in 13 Spanish hospital, on 4070 hospitalized CAP patients, 1529 of whom (37.6%) presented with severe sepsis. Severe sepsis CAP was independently associated with older age (>65 years), alcohol abuse (OR, 1.31; 95% CI, 1.07–1.61), chronic obstructive pulmonary disease (COPD) (OR, 1.75; 95% CI, 1.50–2.04) and renal disease (OR, 1.57; 95% CI, 1.21–2.03), whereas prior antibiotic treatment was a protective factor (OR, 0.62; 95% CI, 0.52–0.73). Bacteremia (OR, 1.37; 95% CI, 1.05–1.79), S pneumoniae (OR, 1.59; 95% CI, 1.31–1.95) and mixed microbial etiology (OR, 1.65; 95% CI, 1.10–2.49) were associated with severe sepsis CAP.
Conclusions
CAP patients with COPD, renal disease and alcohol abuse, as well as those with CAP due to *S pneumonia* or mixed micro-organisms are more likely to present to the hospital with severe sepsis.

Introduction
With an incidence of 3–5 cases per 1000 adults/year, Community-acquired pneumonia (CAP), is a frequent cause of death worldwide [1–3]. A complication of CAP is severe sepsis, the syndrome of infection complicated by systemic inflammation and organ dysfunction. Severe sepsis is a worldwide health problem, with an incidence of 343 cases per 100,000 habitants in the USA. At least one-third of CAP patients present to the hospital with severe sepsis.[4,5]

Initial identification of the severity of sepsis is important in order to institute different management and monitoring measures.[6] Clinicians often do not recognize the presence of severe sepsis in CAP patients, even when organ dysfunction is present. Studies aimed at identifying the CAP population at risk of developing severe sepsis in the community before arriving at hospital are lacking.

The aim of our study was to determine the risk factors for presentation at the hospital with severe sepsis in patients with CAP.

Materials and Methods
Patients and Data Collection
A prospective, multi-center, observational cohort study was carried out in 13 hospitals belonging to the Spanish national health system (CAP Quality Group); a complete, detailed description has been reported in a prior publication.[7] Briefly, the inclusion criterion was a diagnosis of CAP, defined as acute symptoms or signs with a new compatible radiographic lung infiltrate. Exclusion criteria were nursing-home patients, transplant or oncologic patients, leukopenia or neutropenia (unless attributable to pneumonia), Human Immunodeficiency Virus-positive (HIV) patients with severe immunosuppression (CD4 <100), treatment with corticosteroids (>20 mg/day) or other immunosuppressive drugs, and patients with DNR (do not resuscitate) orders or in whom CAP was considered a terminal event. The study was approved by the ethics committee (ISS Hospital La Fe 2004/15 July, Assent 2004/0101) and the patients provided written informed consent.

We recorded data on age, gender, prior antibiotic treatment for the current episode, comorbid conditions (chronic obstructive pulmonary disease [COPD], heart, liver, neurological or renal diseases, and diabetes mellitus), clinical, analytical and radiological results, and the prognostic scales Pneumonia Severity Index (PSI) [8] and CURB65 risk class. [9]

Definitions
Comorbidities were assessed based on clinical history along with prior discharge diagnoses and clinical records, review of medications and results of analyses. [8] Sepsis and severe sepsis were evaluated at CAP diagnosis on hospital admission, following previously accepted criteria. [4,7,10] Sepsis was defined as the presence of pneumonia and systemic inflammatory response syndrome (SIRS). Severe sepsis was considered if criteria for sepsis were met and acute failure of at least one organ was present: arterial hypoxemia (PaO2/FiO2 <300), creatinine >2 mg/dL, acute confusion or hypotension (systolic arterial tension [ST] <90 mmHg). While organ dysfunction has also been defined in terms of hepatic or hematologic failure, information on these organ systems were not available in the data set.
Microbiological Analysis and Diagnostic criteria

Microbiological studies comprised the following: 2550 (62.7%) blood cultures, 3636 (89.3%) urinary antigens for *Legionella pneumophila* and 3654 (89.8%) for *Streptococcus pneumonia*, 1760 (43.2%) sputum cultures, 1902 (46.7%) paired serological studies for *Chlamydia pneumoniae*, *Mycoplasma pneumoniae*, *Coxiella burnetii* and *Legionella pneumophila*, nasopharyngeal swabs to detect viral nucleic acids, invasive samples obtained by bronchoscopy (285 [7%] bronchial aspirate [BAS] and 118 [2.9%] bronchoalveolar lavage [BAL]), and 276 (6.8%) pleural fluid cultures.

Microbiologic diagnostic criteria were the following: 1) positive urinary antigens for *S pneumoniae* and *Legionella pneumophila*; 2) isolation of microorganisms in BAL (≥10⁴ UFC/mL), BAS (≥10⁵ UFC/mL) or in pleural fluid; 3) isolation of one predominant microorganism in sputum or *L pneumophila* in buffered charcoal yeast extract (BCYE) agar; 4) microorganisms in blood culture; 5) seroconversion or a fourfold antibody increase in titers of IgG for *C pneumoniae* (≥1:512), *M pneumoniae* and *C burnetii* (≥1:160) or IgM (≥1:32 for *C pneumoniae*, and ≥1:80 for *M pneumoniae* and *C burnetii*); 5) positive detection of viral nucleic acids in nasopharyngeal swab.

Mixed etiology was defined as pneumonia due to more than one pathogen (virus or bacteria). [11]

Outcome Measurements

The evaluated outcome was mortality during hospitalization and at 30-day and 90-day follow-up. Length of stay (LOS) was defined as the number of days from hospital admission to discharge.

Statistical Study

Data analysis was performed using the SPSS statistical software package, version 15.0. Categorical variable results were expressed as count (percentage) and were compared using the χ² test. Continuous variables were expressed as median with interquartile range (IQR) and were analyzed using non-parametric tests. PSI and CURB65 scales were categorized as low risk (PSI ≤III/ CURB65 ≤2) and high risk (PSI >III/ CURB65 ≥3). Severe sepsis was dichotomized as yes (severe sepsis criteria at hospital admission) and no (non-severe sepsis criteria, the reference group).

Two multivariable statistical studies to predict risk factors for severe-sepsis CAP, the dependent variable, were performed using stepwise logistic regression analyses. In the first model, the included independent variables were those related to characteristics of patients. In the second model, the independent variables were those related to etiology (causal microorganisms). In both models, the independent variables were those found to be significant in the univariate analyses. The Hosmer and Lemeshow goodness-of-fit test was performed to evaluate the adequacy of the models. [12]

Results

Study Population

The cohort comprised 4374 patients presenting to the emergency department with CAP and admitted to hospital. We studied 4070 patients after excluding 237 nursing-home and 66 DNR patients: 1529 (37.6%) had severe-sepsis (Table 1).

Mortality for the whole cohort was 3.3% and the median length of stay was 7 (IQR 4–10) days. Mortality was significantly higher in severe sepsis CAP (Table 2).
Patient Characteristics

Characteristics related to severe sepsis CAP compared to the reference group are shown in Table 1. Severe-sepsis CAP was more frequent in men, patients older than 65 years, and those with COPD and renal disease, whereas diabetes mellitus was more frequent in those without sepsis. Severe-sepsis CAP also presented with higher PSI and CURB65 scores and more multilobar infiltrates. Patients who received prior antibiotic treatment had lower rates of severe-sepsis.

Table 1. Characteristics of CAP with severe sepsis: demographic data, comorbid conditions, radiographic and prognostic scales data.

| Characteristics                            | Severe Sepsis |
|--------------------------------------------|---------------|
|                                            | No, n (%)     | Yes, n (%) | p<sup>c</sup> |
|                                            | n = 2,541     | n = 1,529  |              |
| Demographic data                           |               |            |               |
| Age*                                       | 69 (50–78)    | 73 (60–81) | <0.001       |
| Age ≥65 years                               | 1473 (58.1)   | 1024 (67.1)| <0.001       |
| Male gender                                | 1635 (64.3)   | 1065 (69.7)| 0.001        |
| Current smoker                             | 574 (22.6)    | 343 (22.5) | 0.937        |
| Alcohol abuse<sup>a</sup>                  | 273 (10.7)    | 200 (13.1) | 0.024        |
| Prior corticosteroid treatment<sup>b</sup> | 95 (3.8)      | 74 (4.9)   | 0.083        |
| Prior antibiotic treatment                 | 651 (25.6)    | 261 (17.1) | <0.001       |
| Comorbid condition                         |               |            |               |
| Diabetes Mellitus                          | 566 (22.3)    | 294 (19.2) | 0.200        |
| Liver disease                              | 102 (4)       | 70 (4.6)   | 0.378        |
| Heart disease                              | 346 (13.6)    | 227 (14.8) | 0.277        |
| Renal disease                              | 136 (5.4)     | 132 (8.6)  | <0.001       |
| Neurological disorders                     | 245 (9.7)     | 157 (10.3) | 0.531        |
| COPD                                       | 494 (19.8)    | 477 (32.0) | <0.001       |
| Radiographic findings                      |               |            |               |
| Multilobar infiltrates                     | 501 (19.7)    | 427 (27.9) | <0.001       |
| Pleural Effusion                           | 391 (15.4)    | 248 (16.3) | 0.469        |
| Prognostic scales                          |               |            |               |
| PSI (IV-V)                                 | 866 (34.1)    | 971 (63.5) | <0.001       |
| CURB65 (≥ 3)                               | 531 (20.9)    | 663 (43.3) | <0.001       |

Data are presented as number (percentage) unless otherwise indicated.
*Data are presented as median (interquartile range).
<sup>a</sup> Alcohol abuse: more than 80 g/day.
<sup>b</sup> Previous corticosteroid treatment: less than 20 mg/day prednisone or equivalent.
<sup>c</sup> p value: the χ<sup>2</sup> test was performed for categorical data and the Mann-Whitney U test was performed for continuous data.

doi:10.1371/journal.pone.0145929.t001

Table 2. Length of stay and mortality in CAP with regard to severe sepsis.

| Severe Sepsis | No, n (%) | Yes, n (%) | p value<sup>b</sup> | OR<sup>c</sup> | 95% CI<sup>d</sup> |
|---------------|-----------|------------|----------------------|---------------|--------------------|
| Total No.     | n = 2,541 | n = 1,529  |                      |               |                    |
| LOS<sup>a</sup> | 6 (4–9)   | 8 (5–12)   | <0.001               | 2.404         | 1.773–3.258        |
| Mortality     | 75 (3)    | 104 (6.9)  | <0.001               | 2.404         | 1.773–3.258        |
| At 90 days    | 102 (4.2) | 127 (8.8)  | <0.001               | 2.194         | 1.676–2.872        |

Data are presented as number (percentage) unless otherwise indicated.
<sup>a</sup> LOS: Length of stay (days). Data are presented as median (interquartile range).
<sup>b</sup> p value: the χ<sup>2</sup> test was performed for categorical data and the Mann-Whitney U test was performed for continuous data.
<sup>c</sup> OR: Odds ratio.
<sup>d</sup> CI: Confidence interval.

doi:10.1371/journal.pone.0145929.t002
Etiology

Etiological diagnosis in the whole cohort was reached in 1,506 (37%) patients: 859 (57%) S pneumoniae, 104 (6.9%) L pneumophila, 44 (2.9%) C pneumoniae, 50 (3.3%) C burnetii, 50 (3.3%) M pneumoniae, 45 (3%) Pseudomonas aeruginosa, 43 (2.9%) Haemophilus influen-zae, 18 (1.2%) viruses, 15 (1%) E coli and 121 (8%) mixed etiology.

Severe-sepsis CAP patients had the highest percentage of identified causal microorganisms and more bacteremic episodes. S pneumoniae was the most frequent microorganism found, with a higher percentage in severe sepsis. Atypical microorganisms were more frequent in patients with non-severe sepsis, whereas mixed etiology appeared more often in severe-sepsis CAP. Mixed etiology was caused mainly by S pneumoniae (29.3% with virus or atypical pathogens, 13.8% with Pseudomonas aeruginosa and 5.1% with S aureus) (Table 3).

Multivariable Statistical Analyses

Four independent risk factors related to patients’ characteristics were associated with severe-sepsis CAP: age >65 years, alcohol abuse, renal disease and COPD, whereas prior antibiotic treatment and diabetes were protective factors. With regard to causal microorganisms, S pneumoniae, mixed etiology and bacteremia were found to be risk factors (Table 4).

Discussion

The most important findings of our study were: 1) 37.6% of hospitalized CAP patients had developed community-onset severe sepsis already at admission; 2) elderly patients, alcohol abusers, patients with renal disease and COPD patients were more likely to develop Severe Sepsis in Pneumonia

Table 3. Etiology of CAP in relation to severe sepsis.

| Etiology               | Total No. (%) | Severe Sepsis No, n (%) | p*       |
|------------------------|---------------|-------------------------|----------|
| Total No. n = 2,541   |               | 2,541                   | 1,529    |
| Known etiology n = 1,507 |             | 860 (33.8)              | 646 (42.2) <0.001 |
| Gram-positive n = 866  |               | 466 (18.3)              | 400 (26.2) <0.001 |
| S. pneumoniae n = 859 (21.1) |         | 463 (18.2)              | 396 (25.9) <0.001 |
| MRSA n = 7 (0.2)      |               | 3 (0.1)                 | 4 (0.3)   0.284 |
| Gram-negative n = 207  |               | 123 (4.8)               | 84 (5.5)  0.358 |
| L. pneumophila n = 104 (2.6) |       | 60 (2.4)                | 44 (2.9)  0.312 |
| H. influenza n = 43 (1.1) |             | 25 (1.0)                | 18 (1.2)  0.559 |
| P. aeruginosa n = 45 (1.1) |           | 30 (1.2)                | 15 (1.0)  0.555 |
| E. coli n = 15 (0.4)  |               | 8 (0.3)                 | 7 (0.5)   0.466 |
| Atypical pathogens n = 144 |          | 102 (4.0)               | 42 (2.7)  0.034 |
| C. pneumoniae n = 44 (1.1) |           | 26 (1)                  | 18 (1.2)  0.645 |
| C. burnetii n = 50 (1.2) |           | 37 (1.5)                | 13 (0.9)  0.089 |
| M. pneumoniae n = 50 (1.2) |         | 39 (1.5)                | 11 (0.7)  0.022 |
| Viruses n = 18         |               | 11 (0.4)                | 7 (0.5)   0.908 |
| Mixed etiologyb n = 121 |           | 63 (2.5)                | 58 (3.8)  0.017 |
| Bacteremia n = 284     |               | 137 (9.0)               | 147 (14.5)<0.001 |

Data are presented as number (percentage) unless otherwise indicated.

*p value: the χ² test was performed for categorical data.

b Mixed etiology is defined as pneumonia due to more than one pathogen (virus or bacteria).

doi:10.1371/journal.pone.0145929.t003
community-onset severe sepsis, whereas prior antibiotic treatment was a protective factor; 3) *S. pneumoniae* and mixed etiology are the main causal microorganisms of severe sepsis.

Severe-sepsis CAP is not well characterized in terms of the most susceptible population even though it can appear in over one third of the patients. We have identified the aforementioned characteristics, two of them related to comorbid conditions. However, diabetes was more frequent in those without severe sepsis, probably reflecting more lenient hospitalization criteria in diabetic patients.

At hospital admission, patients with severe-sepsis CAP had higher PSI and CURB65 scores, although more than half of these patients had a CURB65 score \( \leq 2 \), pointing out to the limitations of scales for severity assessment. Patients who had initiated outpatient antibiotic treatment presented a lower frequency of severe-sepsis CAP at hospital arrival. Prior studies have reported the protective effect on mortality when antibiotic therapy was rapidly initiated between 4 and 6 hours after arrival at the hospital. [7,13] Prompt antibiotic administration may rapidly reduce the bacterial load, down-regulating the initial inflammatory cascade and thus decreasing the risk of sepsis. [14,15] On initial severity assessment of CAP, severe sepsis criteria should be taken into account for decision-making process including allocation, monitoring and management. [6]

The multivariable statistical analyses results confirm that alcohol abuse and two comorbid conditions (COPD and renal disease) were independent host risk factors for developing severe-sepsis CAP in the community. The impact of alcohol on developing severe CAP has been linked to an abnormal immune response. [15–18] Curiously, despite the increased risk for severe CAP in COPD patients, mortality is not higher probably due to the use of previous antibiotics and corticosteroids that reduce inflammatory response. [19,20] Our results suggest that patients with alcohol abuse, COPD and renal diseases should be specifically targeted for preventive strategies when in contact with health systems, that is, at discharge or during scheduled outpatient visits. Moreover, if treated as outpatients for CAP, they should be closely monitored and receive instructions to rapidly recognize the signs of sepsis.

Bacteremia and etiological microorganisms are more frequently identified when CAP presents with severe sepsis, most likely due to a higher burden of pathogens in most severe episodes. [2,21] *S. pneumoniae* was the most frequently isolated microorganism in severe CAP.

| Table 4. Multivariable analysis results of severe sepsis related to host factors (first model) and microorganisms (second model). |
|--------------------------------------------------|-----------------------|-----------------|------|
| **First model: Host factors**                    | **Severe Sepsis n = 1,529** | **OR** | **95% CI** | **p** |
| Demographic data and habits                      | Age (\( \geq 65 \) years) | 1.34  | 1.15–1.55 | \(<0.001\) |
|                                                 | Alcohol abuse          | 1.31  | 1.07–1.61 | 0.010  |
| Comorbid condition                               | Diabetes Mellitus      | 0.74  | 0.63–0.88 | \(<0.001\) |
|                                                 | Renal disease          | 1.57  | 1.22–2.03 | 0.001  |
|                                                 | COPD                   | 1.75  | 1.50–2.04 | \(<0.001\) |
| Prior antibiotic treatment                       |                        | 0.62  | 0.52–0.73 | \(<0.001\) |
| **Second model: Microorganisms**                 | **Etiology**           | **OR** | **95% CI** | **p** |
|                                                 | *S. pneumoniae*        | 1.59  | 1.31–1.95 | \(<0.001\) |
|                                                 | *L. pneumophila*       | 1.81  | 1.14–2.86 | 0.012  |
|                                                 | Mixed etiology         | 1.65  | 1.10–2.49 | 0.017  |
|                                                 | Bacteremia             | 1.37  | 1.05–1.79 | 0.021  |

* OR: Odds ratio.

* CI: Confidence interval.

doi:10.1371/journal.pone.0145929.t004
and specifically, some serotypes have been independently associated with septic shock. Mixed etiology was the second most common etiology in severe sepsis CAP, underpinning the impact of associated microorganisms on severity. Patients presenting with severe sepsis should benefit of optimizing microbiological tests to rule out bacteremia and mixed etiology, immediately before initiating a combination antibiotic therapy.

This study has some limitations. We have excluded the nursing-home population and patients with CAP considered a terminal event in order to avoid a different population with different characteristics, more frequent nosocomial infections and/or multidrug resistant microorganisms and limited therapeutic efforts; therefore our findings are not applicable to that subset of population. Second, microbiological diagnosis with regard to viruses was incomplete in a considerable subset of patients, the percentage of blood cultures was suboptimal (62.7%), and determination of _S. pneumoniae_ serotypes was not performed. The indications of microbiological tests in our study relied on the attending physicians. Third, the information regarding septic shock was not recorded. Nevertheless, our strengths are the large sample size and the prospective study design.

**Conclusions**

Elderly patients, alcohol abusers and some comorbidities, such as COPD and renal are predisposing conditions for progressing to severe sepsis CAP in the community, mainly due to _S. pneumoniae_ and mixed etiologies. Those findings may have clinical implications for patients and physicians in primary care and emergency rooms. Preventive CAP strategies such as vaccination—influenza and _S. pneumoniae_—and health measures recommended in guidelines should be reinforced in the most susceptible patients. Recognition of severe-sepsis CAP signals should be encouraged for patients and for physicians in primary care and/or emergency rooms. Initial severity CAP assessment could be improved by evaluation of severe sepsis criteria at diagnosis in order to optimize microbiological and analytical tests, to provide closer monitoring and a rapid antibiotic treatment. Efforts should be directed to encouraging actions to reduce the burden of severe-sepsis CAP episodes and facilitate its prompt recognition.

**Acknowledgments**

NAC Calidad group. IP Rosario Menéndez

B. Montull gelina82@hotmail.com, R. Menéndez rosmenend@gmail.com, S. Reyes solreyes07@gmail.com, R. Méndez rmendezalcoy@gmail.com. Pneumology Department, ISS/Hospital Universitario y Politecnico La Fe. CIBER Enfermedades Respiratorias (CIBERES). Valencia, Spain.

A. Torres. Pneumology Department, Hospital Clínico y Provincial. IDIBAPS, CIBER Enfermedades Respiratorias (CIBERES). Barcelona, Spain. atorres@clinic.ub.es

R. Zalacaín. Pneumology Department, Hospital Cruces, Vizcaya, Spain. rafael.zalacainjorge@osakidetza.net

A. Capelastegui. Pneumology Department, Hospital Galdakao, Vizcaya, Spain. alberto.capelasteguisaiz@osakidetza.net

O. Rajas. olga.rajas@gmail.com, Javier Aspa jaspa@separ.es Pneumology Department, Hospital La Princesa, Madrid, Spain.

L. Borderías. Pneumology Department, Hospital San Jorge, Huesca, Spain. lborderias@salud.aragon.es

J. Martin-Villasclaras. Pneumology Department, Hospital Carlos Haya, Malaga, Spain. jjvillas@gmail.com
S. Bello. Pneumology Department, Hospital Miguel Servet, Zaragoza, Spain. sbello@salud.aragon.es
I. Alfageme. Pneumology Department, Hospital Valme, Sevilla, Spain. ialfageme@separ.es
F. Rodríguez de Castro. Pneumology Department, Hospital Doctor Negrín Las Palmas, Gran Canaria, Spain. frodcasw@gobiernodecanarias.org
J. Rello. Critical Care Department, Hospital Vall Hebron, Universtitat Autonoma de Barcelona, Barcelona, Spain. jrello@crips.es
L. Molinos. Pneumology Department, Hospital Central Asturias, Oviedo, Asturias, Spain. luismol@telefonica.net
J. Ruiz Manzano. Pneumology Department, Hospital Germans Trias i Pujol Badalona, Barcelona, Spain. jruiz@separ.es

Author Contributions
Conceived and designed the experiments: BM R. Menéndez AT. Performed the experiments: SR RZ AC OR LB JMV SB IA FRC JR LM JRM. Analyzed the data: BM SR R. Méndez. Wrote the paper: BM R. Menéndez AT R. Méndez.

References
1. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012; 67: 71–9. doi: 10.1136/thx.2009.129502 PMID: 20729232
2. Rello J. Demographics, guidelines, and clinical experience in severe community-acquired pneumonia. Critical Care. 2008; 12 Suppl 6:S2. doi: 10.1186/cc7025 PMID: 19105795
3. Welte T, Köhnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin Respir Crit Care Med. 2009; 30: 127–35. doi: 10.1055/s-0029-1202941 PMID: 19296412
4. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCp/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003; 29: 530–8. PMID: 12664219
5. Blanco J, Muriel-Bombín A, Sagredo V, Taboada F, Gandía F, Tamayo L, et al. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit care. 2008; 12: R158. doi: 10.1186/cc7157 PMID: 19091069
6. Ewig S, Ruiz M, Mensa J, Marcos MA, Martínez JA, Arancibia F, et al. Severe Community-acquired Pneumonia. Assessment of Severity Criteria. AMJ Respir Crit Care Med. 1998; 158: 1102–8. PMID: 9769267
7. Menéndez R, Torres A, Reyes S, Zalacain R, Capelastegui A, Aspa J, et al. Initial Management Of Pneumonia And Sepsis: factors associated with improved outcome. Eur Respir J. 2012; 39: 156–62. doi: 10.1183/09031936.0018710 PMID: 21828033
8. Fine MJ, AUBLE TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336: 243–50. PMID: 8995084
9. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58: 377–82. PMID: 12728155
10. Dremizov T, Clement G, Kellum JA, Kallassian KG, Fine MJ, Angus DC. Severe Sepsis in Community-Acquired Pneumonia: When does It Happen, and Do Systemic Inflammatory Response Syndrome Criteria Help Predict Course? Chest. 2006; 129: 968–78. PMID: 16608946
11. Cillóniz C, Ewig S, Ferrer M, Polverino E, Gabriàs A, Puig de la Bellacasa J, et al. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Crit Care. 2011; 15: R209. doi: 10.1186/cc10444 PMID: 21914220
12. Hosmer D, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, 1989. Inc ed.
13. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative Study of Community-Acquired Pneumonia Patients Admitted to the Ward and the ICU. Chest. 2008; 133: 610–7. PMID: 17989157
14. Schaaf BM, Boehnke F, Esnaashari H, Seitzer U, Kothe H, Maass M, et al. Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am J Respir Crit Care Med. 2003; 168: 476–80. PMID: 12746253

15. Ruiz M, Ewig S, Torres A, Arancibia F, Marco F, Mensa J, et al. Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med. 1999; 160: 923–9. PMID: 10471620

16. Mehta AJ, Guidot DM. Alcohol abuse, the alveolar macrophage and pneumonia. Am J Med Sci. 2012; 343: 244–7. doi: 10.1097/MAJ.0b013e31823ede77 PMID: 22173040

17. Bertran MJ, Trilla A, Codina C, Camé X, Ribas J, Asenjo MA. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community]. Enferm Infecc Microbiol Clin 2000; 18:445–51. PMID: 11149168

18. de Wit M, Jones DG, Sessler CN, Zilberberg MD, Weaver MF. Alcohol-use disorders in the critically ill patient. Chest. 2010; 138: 994–1003. doi: 10.1378/chest.09-1425 PMID: 20923804

19. Liapikou A, Polverino E, Ewig S, Cillóniz C, Marcos MA, Mensa J, et al. Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients. Eur Respir J. 2012; 39: 855–61. doi: 10.1183/09031936.00067111 PMID: 21920895

20. Almirall J, Bolíbar I, Serra-Prat M, Palomera E, Roig J, Hospital I, et al. Relationship between the use of inhaled steroids for chronic respiratory diseases and early outcomes in community-acquired pneumonia. PLoS One. 2013; 8: e73271. doi: 10.1371/journal.pone.0073271 PMID: 24039899

21. Menéndez R, Sahuquillo-Arce JM, Reyes S, Martínez R, Polverino E, Cillóniz C, et al. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest.

22. Schaaf B, Kruse J, Rupp J, Reinert RR, Droemann D, Zabel P, et al. Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia. Eur Respir J. 2007; 30: 517–24. PMID: 17537775

23. de Roux A, Ewig S, García E, Marcos MA, Mensa J, Lode H, et al. Mixed community-acquired pneumonia in hospitalised patients. Eur Respir J. 2006; 27: 795–800. PMID: 16585087

24. García-Vidal C, Ardanuy C, Tubau F, Viasus D, Dorca J, Liñares J, et al. Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax. 2010; 65: 77–81. doi: 10.1136/thx.2009.123612 PMID: 19996337